Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Net Margin (2016 - 2025)

Historic Net Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 32.84%.

  • Ironwood Pharmaceuticals' Net Margin rose 288600.0% to 32.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.49%, marking a year-over-year increase of 991700.0%. This contributed to the annual value of 29.25% for FY2024, which is 3134100.0% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Net Margin of 32.84% as of Q3 2025, which was up 288600.0% from 27.69% recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Net Margin high stood at 376.14% for Q2 2021, and its period low was 1014.62% during Q2 2023.
  • Its 5-year average for Net Margin is 20.55%, with a median of 35.31% in 2021.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -10527600bps in 2023, then surged by 10137100bps in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Net Margin stood at 35.31% in 2021, then rose by 29bps to 45.58% in 2022, then crashed by -526bps to 194.19% in 2023, then skyrocketed by 159bps to 115.05% in 2024, then crashed by -71bps to 32.84% in 2025.
  • Its last three reported values are 32.84% in Q3 2025, 27.69% for Q2 2025, and 90.87% during Q1 2025.